Massachusetts Cannabis Ballot Measure 2026: Repeal Vote Explained

Executive Summary

Massachusetts voters will decide in November 2026 whether to repeal the state's legal cannabis market through a ballot measure that would eliminate recreational marijuana sales eight years after legalization took effect. The initiative, if approved, would reverse Question 4 from 2016 and shut down the state's regulated adult-use cannabis industry, which generated over $1.8 billion in sales in 2025 and supports more than 15,000 jobs. Advocacy groups on both sides have launched competing advertising campaigns as the vote approaches, with industry-backed coalitions warning of economic consequences and job losses while prohibition advocates cite public health concerns. The measure represents the first serious attempt by any state to repeal recreational cannabis legalization after implementation, making Massachusetts a critical test case for the durability of state-level marijuana reform. Recent polling shows the measure trailing, with approximately 38% of likely voters supporting repeal and 56% opposing, though undecided voters could shift the outcome. The Cannabis Control Commission has prepared contingency plans for potential market shutdown, while multi-state operators with significant Massachusetts investments face uncertainty about asset valuations and future expansion plans.

Why This Matters

The Massachusetts ballot measure carries implications far beyond state borders, testing whether cannabis legalization can be reversed once established and potentially influencing policy debates in dozens of other states. For patients, the measure would eliminate access to recreational dispensaries while preserving the medical marijuana program established in 2012. However, advocates worry that dismantling the larger adult-use infrastructure could reduce product availability, increase prices for medical patients, and force the closure of cultivation facilities that serve both markets. Approximately 78,000 registered medical marijuana patients in Massachusetts depend on the state's 67 licensed medical dispensaries, many of which operate alongside adult-use retail locations. The economic stakes are substantial. Massachusetts cannabis businesses paid $238 million in state taxes in 2025, with municipalities collecting an additional $89 million through local option taxes of up to 3%. The industry directly employs 15,200 workers across cultivation, manufacturing, testing, and retail operations, according to the Massachusetts Cannabis Control Commission. A repeal would trigger immediate layoffs and force the liquidation of inventory, equipment, and real estate holdings valued at approximately $2.1 billion across the supply chain. Multi-state operators including Curaleaf, Trulieve, and Acreage Holdings maintain significant Massachusetts operations, with the state representing between 8% and 15% of revenue for major publicly traded companies. A market shutdown would require asset write-downs and could trigger covenant violations in credit agreements, according to securities filings. Smaller operators face complete business loss, as most Massachusetts-only licensees lack the capital reserves to survive an extended closure or pivot to other markets. The measure also carries symbolic weight as a potential reversal of cannabis normalization. Since Colorado and Washington legalized adult-use sales in 2012, 24 states have followed, creating momentum toward federal reform. A successful repeal campaign in Massachusetts could embolden prohibition advocates in other states and complicate efforts to advance legalization in holdout jurisdictions. Conversely, a decisive defeat of the measure would demonstrate voter commitment to legalization and potentially discourage future repeal attempts.

Background and History

Massachusetts became the first state on the East Coast to legalize recreational cannabis through a 2016 ballot initiative, capping a decade-long evolution from complete prohibition to regulated adult-use sales.

Medical Marijuana Foundation (2012)

Massachusetts voters approved medical marijuana legalization in November 2012 through Question 3, which passed with 63% support. The initiative allowed patients with debilitating conditions including cancer, glaucoma, HIV/AIDS, hepatitis C, Crohn's disease, and Parkinson's disease to access cannabis with physician certification. The law created a regulatory framework administered by the Department of Public Health, establishing licensed dispensaries called Registered Marijuana Dispensaries (RMDs) and cultivation facilities. Implementation proceeded slowly. The first medical dispensaries did not open until June 2015, nearly three years after voter approval, due to regulatory development delays and local opposition to facility siting. By the end of 2015, only 18 RMDs had opened statewide, serving approximately 12,000 registered patients. The program expanded to 35 dispensaries by late 2016, with patient enrollment reaching 38,000.

Question 4 and Adult-Use Legalization (2016)

The Coalition to Regulate Marijuana Like Alcohol gathered sufficient signatures to place Question 4 on the November 2016 ballot. The initiative proposed legalizing possession of up to one ounce of cannabis for adults 21 and older, allowing home cultivation of up to six plants per person (12 per household), and creating a regulated retail market with a 3.75% state excise tax plus local option taxes up to 3%. The campaign divided Massachusetts political leadership. Governor Charlie Baker, Attorney General Maura Healey, and Boston Mayor Marty Walsh opposed the measure, citing concerns about impaired driving, youth access, and public health impacts. Supporters included the Marijuana Policy Project, the Drug Policy Alliance, and the Massachusetts Patient Advocacy Alliance, which argued that legalization would eliminate arrests for simple possession, generate tax revenue, and create a safer alternative to the illicit market. Question 4 passed on November 8, 2016, with 53.7% support, making Massachusetts the first East Coast state to legalize recreational cannabis. The measure received majority support in 229 of 351 cities and towns, with strongest backing in urban areas including Cambridge (71% yes), Somerville (70% yes), and Northampton (69% yes). Opposition concentrated in suburban and rural communities, particularly in Bristol and Plymouth counties.

Legislative Revisions (2017)

Despite voter approval, the Massachusetts Legislature substantially revised Question 4 through Chapter 55 of the Acts of 2017, signed by Governor Baker in July 2017. The legislation increased the state tax rate from 3.75% to 10.75%, delayed retail sales by six months to July 2018, and created the Cannabis Control Commission as an independent regulatory agency replacing the treasurer's office as the implementing authority. The revisions sparked controversy among legalization advocates, who argued that the Legislature had overstepped by altering voter-approved language. However, legal challenges failed, and the Cannabis Control Commission began accepting license applications in April 2018.

Market Launch and Growth (2018-2024)

The first adult-use dispensaries opened in November 2018 in Leicester and Northampton, launching Massachusetts recreational sales. The market expanded rapidly despite initial supply constraints and local opposition. By the end of 2019, 47 adult-use retailers operated statewide, generating $393 million in sales and $51 million in state tax revenue. Growth accelerated through the COVID-19 pandemic, as Massachusetts designated cannabis businesses as essential services. Sales reached $1.3 billion in 2021, $1.6 billion in 2023, and $1.8 billion in 2025. The number of licensed retailers grew to 238 by January 2026, with an additional 89 delivery-only licensees serving customers statewide. The Cannabis Control Commission implemented social equity provisions designed to promote participation by communities disproportionately harmed by prohibition. The Economic Empowerment Priority Certification program provided technical assistance, reduced fees, and priority application review for qualifying applicants. By 2025, approximately 22% of licensed cannabis businesses held social equity certifications, though advocates argued the program had not achieved meaningful ownership diversity due to capital access barriers.

Repeal Movement Formation (2024-2025)

Opposition to legalization coalesced in 2024 around Smart Approaches to Marijuana Massachusetts, a state chapter of the national anti-legalization organization founded by former U.S. Representative Patrick Kennedy. The group began gathering signatures for a ballot initiative to repeal adult-use legalization in March 2024, citing increased emergency room visits for cannabis-related issues, concerns about impaired driving, and opposition to commercialization. The campaign collected 97,500 certified signatures by December 2024, exceeding the 74,574 required to qualify for the ballot. The Massachusetts Attorney General certified the initiative language in January 2025, and the Legislature declined to act on the measure during its constitutional review period, sending it to the November 2026 ballot.

Key Players

Smart Approaches to Marijuana Massachusetts

Smart Approaches to Marijuana Massachusetts leads the repeal campaign as the official committee supporting the ballot measure. The organization is chaired by Dr. Kevin Sabet, a former drug policy advisor in the Obama administration, and includes Massachusetts co-chairs Dr. Sharon Levy, director of the Adolescent Substance Use and Addiction Program at Boston Children's Hospital, and Luke Ryan, a criminal defense attorney who has represented cannabis defendants. The campaign has raised $4.2 million through September 2026, according to filings with the Massachusetts Office of Campaign and Political Finance. Major donors include $1.5 million from the national Smart Approaches to Marijuana organization, $800,000 from the Community Anti-Drug Coalitions of America, and $650,000 from individual donors including casino executive Sheldon Adelson's family foundation.

Coalition to Protect Massachusetts Cannabis

The Coalition to Protect Massachusetts Cannabis formed in January 2026 to oppose the repeal measure. The organization includes the Massachusetts Cannabis Industry Association, the Marijuana Policy Project, the Drug Policy Alliance, and the Massachusetts Recreational Consumer Council. The coalition has raised $18.7 million through September 2026, significantly outpacing repeal advocates. Major contributors include $6.2 million from Curaleaf, $3.8 million from Trulieve, $2.1 million from Acreage Holdings, and $1.9 million from the national Marijuana Policy Project. Additional funding has come from smaller operators, ancillary businesses, and individual donors.

Massachusetts Cannabis Control Commission

The Cannabis Control Commission serves as the state's regulatory authority for both medical and adult-use cannabis. The five-member commission, appointed by the governor, treasurer, and attorney general, oversees licensing, compliance, testing standards, and public health initiatives. Chair Ava Callender Concepcion has stated that the commission has prepared contingency plans for potential market shutdown, including protocols for license revocation, inventory disposal, and facility closure. However, the commission has not taken a formal position on the ballot measure, maintaining regulatory neutrality.

Governor's Office

Governor Maura Healey, who opposed Question 4 in 2016 as attorney general, has not endorsed either side of the 2026 repeal debate. In public statements, Healey has acknowledged both the economic benefits of the legal market and ongoing concerns about youth access and impaired driving. The governor's neutrality represents a shift from her earlier opposition, potentially reflecting political calculations about voter sentiment.

Law Enforcement and Public Health Organizations

The Massachusetts Chiefs of Police Association has endorsed the repeal measure, citing concerns about impaired driving enforcement and increased THC potency in commercial products. The organization argues that legalization has complicated roadside sobriety testing and increased the burden on law enforcement. The Massachusetts Medical Society has not taken a formal position on repeal but has issued statements expressing concern about high-potency cannabis products and inadequate regulation of health claims in marketing. The organization has called for stricter potency limits and enhanced warning labels regardless of the ballot outcome.

Legal and Regulatory Framework

The Massachusetts cannabis regulatory system operates under Chapter 94G of the Massachusetts General Laws, as amended, creating a comprehensive licensing and oversight structure administered by the Cannabis Control Commission. The current legal framework allows adults 21 and older to possess up to one ounce of cannabis in public and up to 10 ounces at home. Home cultivation of up to six plants per person, with a maximum of 12 plants per household, is permitted. Public consumption remains prohibited, with violations subject to civil fines. The commercial market operates under a tiered licensing system including cultivation (indoor, outdoor, and mixed), manufacturing (extraction and infusion), testing laboratories, retail dispensaries, delivery services, and social consumption establishments. Licenses require local approval through host community agreements, background checks, and demonstration of financial capacity and operational plans. The state imposes a 10.75% excise tax on retail sales, comprising a 6.25% state sales tax, a 3.75% cannabis excise tax, and a 0.75% local option tax that municipalities may increase up to 3%. Total tax rates range from 10.75% to 13.75% depending on local decisions. The excise tax revenue is allocated to the Cannabis Control Commission for regulatory operations, with remaining funds distributed to municipalities, public health programs, and the general fund. Testing requirements mandate analysis for potency, pesticides, heavy metals, microbial contaminants, and mycotoxins. Products must meet strict limits, including zero tolerance for E. coli and Salmonella, and maximum levels of 0.3 parts per million for lead and 1.0 parts per million for arsenic. THC potency must be labeled on all products, with separate limits for different product categories. The social equity program, established under 935 CMR 500.105, provides advantages to Economic Empowerment Priority applicants and Social Equity Program participants. Qualifying criteria include residence in areas of disproportionate impact (defined by high drug arrest rates and poverty levels), past cannabis convictions, or status as a minority or woman-owned business. Benefits include priority application review, reduced licensing fees, technical assistance, and access to a Cannabis Social Equity Trust Fund. If the repeal measure passes, Chapter 94G would be repealed effective December 15, 2026, 45 days after the election results are certified. The Cannabis Control Commission would be required to revoke all adult-use licenses, though the medical marijuana program under 105 CMR 725.000 would remain in effect. Existing inventory would need to be destroyed under commission supervision, and facilities would face closure requirements including security protocols and site remediation. The measure does not address several critical implementation questions, including whether employees would qualify for unemployment benefits, how lease terminations would be handled, or whether businesses could seek compensation for regulatory takings. Legal challenges to the repeal are anticipated, potentially arguing that the measure violates contract rights or constitutes an unconstitutional taking of property without just compensation.

State-by-State Context

Massachusetts is the first state with an operational adult-use cannabis market to face a repeal ballot measure, but similar debates have emerged in other legalization states.

Massachusetts

Massachusetts legalized medical marijuana in 2012 and adult-use cannabis in 2016, with retail sales beginning in November 2018. The state allows possession of up to one ounce in public and 10 ounces at home, with home cultivation of up to six plants per person. The combined state and local tax rate ranges from 10.75% to 13.75%. As of September 2026, Massachusetts has 238 adult-use retail licenses and 67 medical dispensaries, with total market sales of $1.8 billion in 2025. The November 2026 ballot measure would repeal adult-use legalization while preserving the medical program.

Colorado

Colorado legalized adult-use cannabis in 2012 through Amendment 64, with sales beginning in January 2014. The state allows possession of up to one ounce and home cultivation of up to six plants. The state excise tax is 15% on wholesale transfers plus a 15% retail sales tax, with local taxes varying by jurisdiction. Colorado has faced no serious repeal efforts, though some municipalities have banned retail sales through local ballot measures. The market generated $1.6 billion in sales in 2025.

California

California legalized adult-use cannabis in 2016 through Proposition 64, with sales beginning in January 2018. The state allows possession of up to one ounce and home cultivation of up to six plants. State taxes include a 15% excise tax plus cultivation taxes of $10.08 per ounce for flower and $3.00 per ounce for leaves. California has not faced statewide repeal efforts, though the illicit market remains larger than the legal market due to high taxes and regulatory costs. Legal sales totaled $4.1 billion in 2025.

Washington

Washington legalized adult-use cannabis in 2012 through Initiative 502, with sales beginning in July 2014. The state allows possession of up to one ounce but prohibits home cultivation for recreational purposes. The state excise tax is 37% of retail price. Washington has not faced repeal efforts, and the market generated $1.2 billion in sales in 2025. The state eliminated its medical marijuana dispensary system in 2016, folding medical sales into the adult-use market.

Oregon

Oregon legalized adult-use cannabis in 2014 through Measure 91, with sales beginning in October 2015. The state allows possession of up to one ounce in public and eight ounces at home, with home cultivation of up to four plants. The state tax is 17% of retail price, with local taxes up to 3%. Oregon has not faced repeal efforts, though oversupply has depressed wholesale prices and forced business closures. Sales totaled $1.1 billion in 2025.

Michigan

Michigan legalized adult-use cannabis in 2018 through Proposal 1, with sales beginning in December 2019. The state allows possession of up to 2.5 ounces and home cultivation of up to 12 plants. The state excise tax is 10% plus a 6% sales tax. Michigan has not faced repeal efforts, and the market has grown rapidly to $2.3 billion in sales in 2025, making it the second-largest state market after California.

Market and Business Implications

A successful repeal would force the immediate closure of Massachusetts cannabis businesses, triggering asset write-downs, layoffs, and potential bankruptcy filings across the supply chain. Multi-state operators face the most significant financial exposure. Curaleaf operates 18 retail locations in Massachusetts plus cultivation and manufacturing facilities, representing approximately 12% of the company's total revenue according to 2025 financial statements. A market shutdown would require asset impairment charges estimated at $180 million to $220 million, based on book values disclosed in securities filings. The company's credit agreement includes financial covenants requiring minimum EBITDA levels that could be jeopardized by a sudden revenue loss of this magnitude. Trulieve operates 11 Massachusetts locations contributing approximately 8% of company revenue. The company has invested heavily in Massachusetts real estate, owning rather than leasing most facilities. A repeal would leave Trulieve with properties that have limited alternative use, particularly purpose-built cultivation facilities with specialized HVAC, lighting, and security systems. The company would likely seek to sell properties but would face a flooded market as all operators attempt simultaneous liquidation. Smaller operators face existential threats. Massachusetts-only licensees lack the geographic diversification to absorb a complete market loss. Many operators carry significant debt from facility buildouts and working capital needs, with loans secured by licenses, inventory, and equipment that would become worthless upon repeal. Bankruptcy filings would likely follow, with creditors competing for limited asset value. Wholesale prices would collapse immediately upon passage as cultivators rush to liquidate inventory before the December 15, 2026 effective date. Industry analysts project wholesale flower prices could fall from current levels of $1,800 to $2,200 per pound to under $500 per pound as supply overwhelms demand in the compressed timeline. Some operators might attempt to transfer inventory to other state markets, but interstate commerce remains prohibited under federal law, limiting options to destruction or fire-sale pricing. Ancillary businesses including testing laboratories, security companies, packaging suppliers, and software vendors would lose Massachusetts clients, though some could pivot to serving other state markets or medical-only operations. Real estate investors who purchased properties leased to cannabis tenants face vacancy and reduced property values, particularly for specialized facilities. The social equity program would be devastated. Economic Empowerment Priority licensees, many of whom opened businesses within the past three years, would lose investments before achieving profitability. The program was designed to address harms from prohibition; repeal would compound those harms by eliminating the economic opportunities created to provide redress. Tax revenue losses would impact state and municipal budgets. The $238 million in state cannabis tax revenue collected in 2025 funds Cannabis Control Commission operations, public health programs, and general government services. Municipalities collected $89 million in local option taxes, with some communities heavily dependent on cannabis revenue. The town of Leicester, home to one of the state's first dispensaries, derives approximately 18% of its annual budget from cannabis taxes and host community agreement payments. Employment impacts extend beyond direct cannabis jobs. The 15,200 workers employed by licensed cannabis businesses would face immediate layoffs, increasing unemployment insurance claims and reducing consumer spending. Indirect employment in construction, professional services, and retail sectors supporting the cannabis industry would also contract.

What Experts Say

Policy analysts, economists, and public health researchers have offered sharply divergent assessments of the repeal measure's likely impacts. According to the Beacon Hill Institute, a Boston-based economic research organization, repeal would eliminate approximately 15,200 direct jobs and an additional 8,700 indirect jobs in supporting industries. The organization's analysis, released in August 2026, projected total economic output losses of $2.8 billion annually, including $1.8 billion in direct cannabis sales, $620 million in supply chain activity, and $380 million in induced economic effects from employee spending. Dr. Angela Hawken, a professor of public policy at New York University who studies cannabis regulation, said in a September 2026 interview that Massachusetts repeal would create a natural experiment testing whether legalization can be reversed. Hawken noted that prohibition enforcement costs would return, including arrests, prosecutions, and incarceration expenses, while tax revenue would disappear. She estimated that Massachusetts could face $45 million to $65 million in annual criminal justice costs related to cannabis enforcement if prohibition is restored, based on pre-legalization data adjusted for inflation. The RAND Corporation released a report in July 2026 examining potential public health impacts of repeal. The analysis found that cannabis use rates among Massachusetts adults had increased from 16.8% in 2016 to 21.3% in 2025, but noted that similar increases occurred in non-legalization states over the same period, suggesting broader social trends beyond policy changes. The report concluded that repeal would likely reduce commercial availability but would not eliminate use, instead shifting consumption to illicit markets with unknown product safety and potency. Dr. Kevin Sabet, president of Smart Approaches to Marijuana, said in campaign materials that legalization has failed to eliminate the illicit market while creating a commercialized industry that markets high-potency products to maximize profits. Sabet cited Massachusetts Poison Control Center data showing cannabis exposure calls increased from 312 in 2018 to 891 in 2025, arguing that legalization has created public health harms that justify repeal. Jim Borghesani, communications director for the Coalition to Protect Massachusetts Cannabis and a veteran of the 2016 legalization campaign, said in a September 2026 press conference that repeal would return Massachusetts to a failed prohibition policy that disproportionately harmed communities of color. Borghesani noted that cannabis arrests in Massachusetts fell from 8,421 in 2016 to 347 in 2025, with the remaining arrests primarily for illegal sales rather than possession. According to Bethany Moore, an economist at the University of Massachusetts Amherst who studies cannabis markets, repeal would create significant transition costs beyond direct business losses. Moore's research, published in September 2026, estimated that property value declines in areas with cannabis business concentrations could total $340 million to $480 million as commercial real estate loses anchor tenants and foot traffic declines. The Massachusetts Budget and Policy Center, a nonprofit research organization, released an analysis in August 2026 projecting that repeal would create a state budget gap of $190 million to $220 million annually, including $238 million in lost tax revenue partially offset by $48 million in reduced Cannabis Control Commission operating costs. The organization noted that municipalities would lose $89 million in local option taxes and host community agreement payments, forcing property tax increases or service cuts.

What's Next

The November 3, 2026 election will determine whether Massachusetts becomes the first state to repeal adult-use cannabis legalization, with implementation beginning in mid-December if the measure passes. Early voting begins on October 21, 2026, with mail ballots available starting October 14, 2026. The Coalition to Protect Massachusetts Cannabis has scheduled a final advertising push for the two weeks before Election Day, with television, digital, and direct mail campaigns targeting undecided voters in suburban swing communities. Smart Approaches to Marijuana Massachusetts plans grassroots mobilization including phone banking and door-to-door canvassing in areas that opposed Question 4 in 2016. If the measure fails, the cannabis industry would continue operating under current regulations, though the Cannabis Control Commission has indicated it may propose potency limits and enhanced packaging requirements in response to public health concerns raised during the campaign. The commission's regulatory review process would begin in early 2027, with public hearings scheduled for February and March. If the measure passes, implementation would proceed on an accelerated timeline. The repeal would take effect on December 15, 2026, 45 days after the State Secretary certifies election results. The Cannabis Control Commission would be required to notify all adult-use licensees of immediate revocation, with a 30-day wind-down period for inventory disposal and facility closure. Retail sales would cease on December 15, 2026, with cultivation and manufacturing operations required to destroy remaining inventory under commission supervision by January 15, 2027. Legal challenges are anticipated regardless of the outcome. If repeal passes, industry groups are expected to file lawsuits arguing that the measure constitutes an unconstitutional taking of property without just compensation, violates contract rights, or exceeds the scope of the initiative petition process. These challenges would likely seek preliminary injunctions delaying implementation while courts consider the merits, potentially extending operations into 2027. The Massachusetts Legislature could intervene after the election. If repeal passes narrowly, legislators might propose a compromise measure restoring limited legalization with stricter regulations, such as lower potency limits, reduced retail license caps, or enhanced local control. However, any legislative action would require a two-thirds supermajority to amend a voter-approved initiative within three years, making intervention politically difficult. Federal policy changes could influence the Massachusetts debate. The Drug Enforcement Administration's ongoing review of cannabis scheduling under the Controlled Substances Act could result in rescheduling from Schedule I to Schedule III, which would reduce federal criminal penalties and allow state-legal businesses to deduct normal business expenses under Internal Revenue Code Section 280E. A federal policy shift toward accommodation of state legalization could undermine repeal arguments, while continued federal prohibition could strengthen them. Other states are watching Massachusetts closely. If repeal succeeds, prohibition advocates in states including Arizona, Montana, and New Jersey have indicated they would pursue similar ballot measures. Conversely, a decisive defeat would likely discourage repeal efforts and strengthen the case for legalization in states considering reform. The social equity program's future depends on the election outcome. If legalization survives, advocates plan to push for expanded funding and technical assistance to address capital access barriers that have limited program effectiveness. If repeal passes, Economic Empowerment Priority licensees would lose their businesses, and the program would be eliminated, erasing progress toward addressing prohibition's disproportionate impact on communities of color.

Further Reading

• Massachusetts General Laws Chapter 94G: Regulation of the Use and Distribution of Marijuana Not Medically Prescribed - https://malegislature.gov/Laws/GeneralLaws/PartI/TitleXV/Chapter94G
• Cannabis Control Commission Official Website and Regulations (935 CMR 500.000) - https://masscannabiscontrol.com/
• Question 4 Ballot Text and Results (November 2016) - https://www.sec.state.ma.us/ele/ele16/ballot_questions_16/quest4.htm
• Massachusetts Office of Campaign and Political Finance - Campaign Finance Reports for Ballot Question Committees - https://www.ocpf.us/
• Chapter 55 of the Acts of 2017: An Act to Ensure Safe Access to Marijuana - https://malegislature.gov/Laws/SessionLaws/Acts/2017/Chapter55
• Cannabis Control Commission Annual Reports (2018-2025) - https://masscannabiscontrol.com/about/annual-reports/
• Massachusetts Department of Public Health Medical Marijuana Program (105 CMR 725.000) - https://www.mass.gov/medical-use-of-marijuana-program
• Beacon Hill Institute Economic Impact Analysis (August 2026) - http://www.beaconhill.org/
• RAND Corporation Report: Public Health Implications of Cannabis Policy in Massachusetts (July 2026) - https://www.rand.org/
• Massachusetts Budget and Policy Center Fiscal Analysis (August 2026) - https://massbudget.org/